Key result
Buffered aspirin and enteric-coated aspirin showed no significant difference in the incidence of overt gastrointestinal bleeding (3.7% vs 3.9%, p=0.92) in patients with cardiovascular disease.
Why the study?
Does the formulation of low-dose aspirin (enteric-coated vs buffered) affect the incidence of gastrointestinal bleeding in patients with cardiovascular disease?
Population
1402 patients with cardiovascular disease, including 701 receiving long-term low-dose aspirin for >1 year…
Comparison
Enteric-coated low-dose aspirin taken for more… vs Buffered low-dose aspirin taken for more than 1…
Design
Cohort
Follow-up
median 1778 ± 747 days
Authors
Loading...
No formulation preference warranted to reduce overt GI bleeding; leaves open differences in occult loss and needs randomized confirmation.
Cohort (n=1,402)
Does the formulation of low-dose aspirin (enteric-coated vs buffered) affect the incidence of gastrointestinal bleeding in patients with cardiovascular disease?
Absolute Event Rate: 3.7% vs 3.9%
p-value: p=0.92
Enteric-coated aspirin does not reduce overt gastrointestinal bleeding compared to buffered aspirin in cardiovascular patients, and may trend toward higher rates of occult small bowel blood loss.
Hirata et al. (2011) conducted a cohort in cardiovascular disease (n=1,402). Buffered aspirin vs. Enteric-coated aspirin was evaluated on overt GI bleeding (p=0.92). Buffered aspirin and enteric-coated aspirin showed no significant difference in the incidence of overt gastrointestinal bleeding (3.7% vs 3.9%, p=0.92) in patients with cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: